<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <link rel="shortcut icon" href="../images/favicon.png" type="image/x-icon">
  <title>Ebola Virus Disease</title>
  <link href="https://cdn.jsdelivr.net/npm/remixicon@2.5.0/fonts/remixicon.css" rel="stylesheet">
  <link rel="stylesheet" href="../style.css">
  <link rel="stylesheet" href="../notes.css">
</head>
<body>
  <input type="checkbox" id="main-navigation-toggle" class="btn btn--close" title="Toggle main navigation" />
  <label for="main-navigation-toggle">
    <span></span>
  </label>
  
  <a href="../index.html">
   <div class="home-navigation">
      mtr<span class="logo-dot">.</span>
    </div>
  </a>

    <nav id="main-navigation" class="nav-main">
    <ul class="menu">
      <li class="menu__item">
        <a class="menu__link" href="../index.html">Home</a>
      </li>

      <li class="menu__item">
        <a class="menu__link" href="../about-temp2.html">About</a>
      </li>
    </ul>
  </nav>
  
      <!-- Toggle switch for dark mode -->
      <div class="dark-mode-toggle">
        <label class="switch-toggle">
            <input type="checkbox" id="dark-mode-toggle-checkbox">
            <span class="toggle-slider"></span>
        </label>
      </div>
      
  <main class="page-container">
    <div class="contribute-cta">
      <p>Help make this betterüíú</p>
      <span><a href="../contribute.html">Contribute here</a> </span>
    </div>

    <h1>Ebola Virus Disease</h1>
  
    <!-- <div class="author-flex">
      <div class="author-img">
        <img  src="/contributors/vt1.jpeg" alt="">
      </div>
      <div>
        <h2 class="name">Compiled by Victortayo</h2>
        <p class="updated">last updated, Nov 2022</p>
      </div>
    </div> -->

    <article class="notes">
        <a id='top'></a>
    <article>
    <!-- <h2 class='title'>Outline</h2> -->
    <div class="outline2">

      <input type="radio" name="control-2" id="show-2">
      <label for="show-2">Show Outline</label>
      <input type="radio" name="control-2" id="hide-2">
      <label for="hide-2">Hide Outline</label>
      <div class="contents">
         <ol>
            <li><a href="#header-1">Introduction  </a></li>
            <li><a href="#header-2">Epidemiology </a></li>
            <li><a href="#header-3">Classification </a></li>
            <li><a href="#header-4">Transmission </a></li>
            <li><a href="#header-5">Pathogenesis</a></li>
            <li><a href="#header-6">Clinical manifestation</a></li>
            <li><a href="#header-7">Diagnosis </a></li>
            <li><a href="#header-8">Treatment </a></li>
            <li><a href="#header-9">Control</a></li>
            <li><a href="#header-10">Monitoring and Evaluation</a></li>
         </ol>
      </div>
     <div>

      <br>

      <section id='header-1'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-1'>Introduction  </a>
          </h2>
        </header>
        <div class='body'>
            <ul>
                <li>Ebola is a disease of humans and other primates caused by ebola viruses, which is a severe, often fatal illness in humans.</li>
                <li>The average EVD case fatality rate is around 50%. Case fatality rates have varied from 25% to 90% in past outbreaks.</li>
                <li>EVD first appeared in 1976 in 2 simultaneous outbreaks, one in Sudan and the other in DRC (near the Ebola River which gave its name).</li>
            </ul>
        </div>

      </section>

      <section id='header-2'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-2'>Epidemiology </a>
          </h2>
        </header>
        <div class='body'>
            <ul>
                <li>It has also spread between countries starting in Guinea to Sierra Leone, Senegal and Liberia (by land) and to Nigeria (by air).</li>
                <li>The most severely affected countries were Guinea, Sierra Leone and Liberia due to their very weak health systems.</li>
                <li>Year 1976 marked the first outbreak of Ebola (Sudan) which infected over 284 people with MR of 53%, few months later, second outbreak (Zaire) infected 318 with MR of 88%.</li>
            </ul>
            
            <figure>
                <img src="../figures/ebola (15).png" alt="">
                <figcaption> Geographic distribution of Ebola virus disease outbreaks in humans and animals</figcaption>
            </figure>

            <figure>
                <img src="../figures/ebola (7).png" alt="">
                <figcaption> Ebola outbreaks</figcaption>
            </figure>

            <figure>
                <img src="../figures/ebola (6).png" alt="">
                <figcaption>EVD cases and deaths </figcaption>
            </figure>

            <ul>
                <li>In 1989, the third outbreak (Reston) was identified in Monkeys, no single infected person developed VHF.</li>
                <li>In 1994, the fourth strain of (Cote d‚ÄôIvoire).</li>
                <li>The March, 2014 Ebola outbreak is the largest and most complex Ebola outbreak in history and the first in West Africa.</li>
                <li>On August 8 2014, the WHO Director- General declared this outbreak a Public health Emergency of International Concern.</li>
                <li>WHO identified gorillas and chimpanzees as ‚Äúnatural hosts‚Äù, however, experts identify them as mere ‚Äúaccidental hosts‚Äù because a large number of them are killed by the virus.</li>
                <li>Further research shows that fruit bats are reservoirs of Ebola virus</li>
            </ul>

        </div>
      </section>

      <section id='header-3'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-3'>Classification </a>
          </h2>
        </header>
        <div class='body'>
            <ul>
                <li>Order: Mononegavirales</li>
                <li>Family: Filoviridae</li>
                <li>Genus: Ebola like viruses</li>
                <li>Species: Ebola</li>
                <li>Subtypes</li>
                <ul>
                    <li>Ebola-Zaire, Ebola- Sudan, Ebola-Ivory Coast disease in humans</li>
                    <li>Ebola-Reston disease in nonhuman primates</li>
                </ul>
            </ul>
        </div>
      </section>

      <section id='header-4'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-4'>Transmission </a>
          </h2>
        </header>
        <div class='body'>
            <ul>
                <li>Virus present in high quantity in blood, body fluids, and excreta of symptomatic EVD-infected patients</li>
                <li>Opportunities for human-human transmission</li>
                <ul>
                    <li>    Direct contact (blood, fluid or meat of an infected animal or person)</li>
                    <li>    Indirect contact</li>
                    <li>    Sharps injury</li>
                    <li>    Exposure to corpse of person who died of EVD</li>
                </ul>
                <li>Note: semen can test positive after clinical clearance for up to three months (CDC, 2015)</li>
                <li>Incubation period: Patients with EVD typically have an abrupt onset of symptoms 6 to 12 days after exposure (range 2 to 21 days).</li>
            </ul>

            <figure>
                <img src="../figures/ebola (5).png" alt="">
                <figcaption>Transmission  </figcaption>
              </figure>
        </div>
      </section>

      <section id='header-5'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-5'>Pathogenesis</a>
          </h2>
        </header>
        <div class='body'>
            <ul>
                <li>Direct infection of tissues</li>
                <li>Immune dysregulation</li>
                <li>Disseminated intravascular coagulation (DIC) and coagulopathy</li>
                <li>Hypovolemia and vascular collapse</li>
                <ul>
                    <li>    Electrolytes abnormalities</li>
                    <li>    Multi-organ failure, septic shock</li>
                </ul>
                <li>Death </li>
            </ul>
        </div>
      </section>

      <section id='header-6'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-6'>Clinical manifestation</a>
          </h2>
        </header>
        <div class='body'>
           <p>Acute onset‚Äî typically 6-12 days after exposure (range 2-21 days)</p>
           <p>Signs and symptoms</p>
           <ul>
            <li>Initial: fever, chills, myalgia, malaise, anorexia</li>
            <li>After 5 days: GI symptoms</li>
            <li>Later: haemorrhage (not common, hence, EVD and not EHF)</li>
            <li>Others: Headache, conjunctivitis, hiccups, rash, chest pain, shortness of breath, confusion, seizures.</li>
           </ul>

           <figure>
            <img src="../figures/ebola (11).png" alt="">
            <figcaption>Symptoms of Ebola </figcaption>
          </figure>

          <figure>
            <img src="../figures/ebola (16).png" alt="">
            <figcaption>Examples of haemorrhagic signs </figcaption>
          </figure>

          <figure>
            <img src="../figures/ebola (12).png" alt="">
            <figcaption>Clinical manifestation </figcaption>
          </figure>
        </div>
      </section>

      <section id='header-7'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-7'>Diagnosis  </a>
          </h2>
        </header>
        <div class='body'>
           <ul>
            <li>RT-PCR sample collection</li>
            <ul>
                <li>Volume: minimum volume of 4mL of whole blood in an EDTA plastic bottles</li>
            </ul>
            <li>Sample testing</li>
            <ul>
                <li>RT-PCR to diagnose acute infection (for identification of specific viral genetic fragments) Gold standard.</li>
                <li>Virus isolation</li>
                <li>Immunohistochemical staining and histopathology</li>
                <li>Serologic testing for IgM and IgG antibodies (ELISA)</li>
            </ul>
            <li>Laboratory findings</li>
            <ul>
                <li>Thrombocytopenia (50,000-100,000/mL range)</li>
                <li>Leukopenia followed by neutrophilia</li>
                <li>Transaminase elevation: AST>ALT</li>
                <li>Electrolyte abnormalities from fluid shifts</li>
                <li>Coagulation: PT and PTT prolonged</li>
                <li>Renal: proteinuria, increased creatinine</li>
            </ul>
            <li>Differential diagnosis: Malaria, typhoid fever, meningococcemia, Lassa fever, Acute surgical abdomen, Crimean-Congo hemoharrgic fever, Marburg HF, and some bacterial infections</li>
           </ul>
        </div>
      </section>

      <section id='header-8'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-8'>Treatment  </a>
          </h2>
        </header>
        <div class='body'>
           <ul>
            <li>Supportive care</li>
            <ul>
                <li>Fluid and electrolyte replacement</li>
                <li>Respiratory support</li>
                <li>Antimicrobial therapy</li>
            </ul>
            <li>Symptomatic care</li>
            <ul>
                <li>Fever (avoid NSAID)</li>
                <li>Correction of severe coagulopathy </li>
                <li>Renal replacement therapy</li>
            </ul>
            <li>Ebola-specific: Immazeb and Ansuvimab</li>
           </ul>

           <figure>
            <img src="../figures/ebola (3).jpg" alt="">
            <figcaption> Ebola diagnosis</figcaption>
          </figure>
        </div>
      </section>

      <section id='header-9'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-9'> Control</a>
          </h2>
        </header>
        <div class='body'>
           <li>Primary</li>
           <ul>
            <li>Avoidance of unnecessary travel, direct and indirect contacts, attending burials and bush meats consumption.</li>
            <li>Health promotion</li>
            <li>A large number of health workers should be trained; in infection control measures, setting up an epidemiological surveillance network and promoting public health messages.</li>
            <li>Appropriate use of PPE</li>
            <li>Vaccination (rVSV-ZEBOV and Ad26.ZEBOV vaccines)</li>
           </ul>
           <li> Secondary </li>
           <ul>
            <li>Health care personnels should have high index of suspicion, be able to identify cases, follow up with and trace cases and their contacts.</li>
            <li>Health facilities should be well equipped both with human and material resources to provide optimum care and treatment.</li>
            <li>Setting up of treatment centres and transit units close to affected villages.</li>
           </ul>
           <li>Tertiary </li>
           <ul>
            <li>Ebola creates fear inside communities, and sick people are often stigmatized. Psychological support is provided to patients and their families. </li>
            <li>The health workers should organize participatory health promotion activities with healed patients.</li>
           </ul>

           <figure>
            <img src="../figures/ebola (17).png" alt="">
            <figcaption> </figcaption>
          </figure>
        </div>
      </section>

      <section id='header-10'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-10'>Monitoring and Evaluation </a>
          </h2>
        </header>
        <div class='body'>
           <p>Initial assessment for Ebola Virus Disease</p>
           <ul>
            <li>The risk of exposure to Ebola virus helps us to guide the evaluation and monitoring of both symptomatic and asymptomatic individuals.</li>
            <li>Patients are risk of EBV if they had an exposure that occurred within 21 days before the onset of symptoms.</li>
            <li>However, the level of exposure risk range from high to low to no known identifiable risk. For health care workers, the level of exposure risk can vary depending upon the intensity of the epidemic at their work site.</li>
           </ul>

           <figure>
            <img src="../figures/ebola (10).png" alt="">
            <figcaption>EVD risk assessment </figcaption>
          </figure>

          <figure>
            <img src="../figures/ebola (9).png" alt="">
            <figcaption> EVD risk assessment</figcaption>
          </figure>

          <figure>
            <img src="../figures/ebola (2).png" alt="">
            <figcaption> EVD algorithm for evaluation of the returned traveller</figcaption>
          </figure>

          <figure>
            <img src="../figures/ebola (8).png" alt="">
            <figcaption> Interim guidance for monitoring and movement of persons with EVD</figcaption>
          </figure>

          <figure>
            <img src="../figures/ebola (2).jpg" alt="">
            <figcaption> Stopping the outbreak</figcaption>
          </figure>



      <section id='heading-1-2-1'>
        <header>
          <h4>

            <a aria-hidden href='#heading-1-2-1'></a>
          </h4>
        </header>
        <div class='body'>
            <p></p>
            <p></p>

        </div>
      </section>

      </section>

      <div class="contact">
        <hr style="margin: 3rem 0;">

        <div class="comment">
        <p>Send your comments, corrections, explanations/clarifications and requests/suggestions to our <a href="https://chat.whatsapp.com/FtDdb6uEFYzBCnTnMgm2Z1">WhatsApp group</a>.</p>
        </div>
      </div>
    </article>
   </article>
   <div style="height: 300px;"></div>
  </main>

  <footer>
    <div class="footer-container">
        <div>
          <p id="popup-trigger">disclaimer</p>

          <!-- The pop-up dive content -->
          <div id="popup" class="popup">
            <p>The content on this ‚ÄòWebsite‚Äô, including but not limited to text, graphics, images, videos, and other materials, should not be considered as a substitute for formal medical education or clinical training. The creators and operators of this Website make no warranties, express or implied, regarding the accuracy, currency, or completeness of the information provided on the Website. They shall not be held responsible for any errors or omissions, or for any actions taken based on the information provided on this Website.</p>
            <button class="popup-close" onclick="closePopup()">Close</button>
          </div>     
          <p><a href="../about-temp2.html">about</a> </p>   
          <p><a href="../contribute.html">contribute</a> </p>
        </div>

        <div class="footer-beta">
          <p>thisisatestversion</p>
        </div>
    </div>
  </footer>
<!------------  SCROLL UP ----------->
<a href="#" class="scrollup" id="scroll-up"> 
  <i class="ri-arrow-up-fill scrollup__icon"></i>
</a>
<script src="../main.js"></script>
<script src="../modal.js"></script>
</body>
</html>
 
